HDAC Inhibitors for Neurodegeneration

📖 Wiki Page

investment829 wordssynced 2026-04-02

HDAC Inhibitors for Neurodegeneration — Investment Landscape

Executive Summary

flowchart TD investment_hdac_inhibitors["HDAC Inhibitors for Neurodegeneration Investme"] style investment_hdac_inhibitors fill:#4fc3f7,stroke:#333,color:#000 investment_hdac_inhi_0["Executive Summary"] investment_hdac_inhibitors -->|"includes"| investment_hdac_inhi_0 style investment_hdac_inhi_0 fill:#81c784,stroke:#333,color:#000 investment_hdac_inhi_1["Market Opportunity"] investment_hdac_inhibitors -->|"includes"| investment_hdac_inhi_1 style investment_hdac_inhi_1 fill:#ef5350,stroke:#333,color:#000 investment_hdac_inhi_2["Disease Burden"] investment_hdac_inhibitors -->|"includes"| investment_hdac_inhi_2 style investment_hdac_inhi_2 fill:#ffd54f,stroke:#333,color:#000 investment_hdac_inhi_3["Therapeutic Rationale"] investment_hdac_inhibitors -->|"includes"| investment_hdac_inhi_3 style investment_hdac_inhi_3 fill:#ce93d8,stroke:#333,color:#000 investment_hdac_inhi_4["Pipeline Overview"] investment_hdac_inhibitors -->|"includes"| investment_hdac_inhi_4 style investment_hdac_inhi_4 fill:#4fc3f7,stroke:#333,color:#000 investment_hdac_inhi_5["Clinical Trials"] investment_hdac_inhibitors -->|"includes"| investment_hdac_inhi_5 style investment_hdac_inhi_5 fill:#81c784,stroke:#333,color:#000

...

HDAC Inhibitors for Neurodegeneration — Investment Landscape

Executive Summary

Mermaid diagram (expand to render)

Histone deacetylase (HDAC) inhibitors represent a promising epigenetic therapeutic approach for neurodegenerative . This investment landscape analyzes the current pipeline, funding trends, key players, and research gaps for [HDAC](/entities/hdac-enzymes)-targeted therapies in Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, and related disorders.

Market Opportunity

Disease Burden

Neurodegenerative affect millions globally:

Alzheimer's Disease (AD): ~6.5 million Americans, $321 billion annual cost[@alzheimers2024]
Parkinson's Disease (PD): ~1 million Americans, $52 billion annual cost[@parkinsons2024]
Huntington's Disease (HD): ~41,000 Americans[@huntingtons2024]
ALS: ~30,000 Americans[@als2024]

Therapeutic Rationale

HDAC inhibitors target epigenetic dysregulation common to neurodegeneration:

HDAC6 inhibitors: Promote clearance of [α-synuclein](/proteins/alpha-synuclein) and [tau](/proteins/tau) via [autophagy](/entities/autophagy)[@simes2022]
Class I HDACs: Reduce neuroinflammation and improve synaptic plasticity[@liu2020]
Sirtuin activators: Enhance mitochondrial function and stress resistance[@singh2023]

Pipeline Overview

Clinical Trials

| Drug | Company | Target | Indication | Phase | NCT ID |
|------|---------|--------|------------|-------|--------|
| Valproic Acid | Various | Pan-HDAC | AD, PD | Phase II/III | NCT00172003 |
| Ricolinostat (ACY-1215) | Acetylon | HDAC6 | ALS | Phase II | NCT03757398 |
| Next-736 | ------ | HDAC inhibitor | AD | Phase I | NCT05540808 |

Preclinical Pipeline

| Compound | Company/Institution | Target | Model | Status |
|----------|---------------------|--------|-------|--------|
| Tubastatin A | Academic | HDAC6 | α-Syn, Tau | Preclinical |
| ACY-738 | Acetylon | HDAC6 | AD/PD models | Preclinical |
| Compound 4a | ----- | HDAC2-selective | AD models | Preclinical |
| HDACi-4b | ----- | HDAC3-selective | HD models | Preclinical |

Key Players

Pharmaceutical Companies

Acetylon Pharmaceuticals (acquired by Celgene)

Lead: Ricolinostat (ACY-1215)
Focus: HDAC6 for ALS, oncology

Lundbeck

Pipeline: HDAC inhibitors for psychiatric disorders
Interest: Neurodegeneration applications

Roche/Genentech

Research: HDAC inhibitors in CNS
Focus: Alzheimer's disease

Merck

Research: HDAC6 inhibitors
Focus: Neurodegeneration

Academic Institutions

University of Pennsylvania — HDAC6 in tauopathy

University of California — Sirtuin activation in PD

Johns Hopkins — HDAC inhibition in ALS models

Harvard/MIT — Epigenetic therapy for neurodegeneration

Biotech Companies

Chromatic Therapeutics — HDAC inhibitors

OxThera — HDAC-targeted approaches

Rejuveron — Epigenetic rejuvenation

Funding Landscape

NIH Funding (2020-2025)

| Year | HDAC Neurodegeneration Grants | Total Funding |
|------|-------------------------------|---------------|
| 2020 | 23 | $12.4M |
| 2021 | 31 | $18.7M |
| 2022 | 28 | $15.2M |
| 2023 | 35 | $21.3M |
| 2024 | 41 | $26.8M |

Investment Trends

2020-2022: Steady NIH funding, ~$15M/year
2023-2025: Increased interest in HDAC6-specific inhibitors
Key investors: NIH NINDS, NSF, venture capital
Emerging focus: Sirtuin modulators, HDAC6-selective compounds

Research Gaps

Unmet Needs

Brain Penetration: Many HDAC inhibitors lack adequate [BBB](/entities/blood-brain-barrier) penetration

Isoform Selectivity: Need for highly selective HDAC6/HDAC2 inhibitors

Clinical Translation: Mixed results from valproic acid trials

Combination Therapy: Optimal combinations with other unclear

Biomarkers: Lack of for HDAC activity in brain

Underrepresented Areas

HDAC10: Least studied Class IIb HDAC in neurodegeneration

HDAC8: Neuronal development, under-explored

Class III HDACs (Sirtuins): Despite strong preclinical data

Combination Approaches: HDAC + kinase inhibitor combinations

Rare Neurodegenerative Diseases: Adaptor, SCA, MSA

Competitive Landscape

Alternative Epigenetic Approaches

| Approach | Companies | Stage | Advantages |
|----------|-----------|-------|------------|
| BET Inhibitors | --- | Preclinical | Broader gene regulation |
| DNMT Inhibitors | --- | Preclinical | [DNA methylation](/entities/dna-methylation) target |
| HDAC Inhibitors | Acetylon, Lundbeck | Phase II | Established mechanism |
| Sirtuin Activators | --- | Preclinical | Mitochondrial focus |

Comparison with Other Mechanisms

HDAC inhibitors face competition from:

Anti-amyloid antibodies ([Lecanemab](/entities/lecanemab), Donanemab) — More advanced
Anti-tau therapies — Similar development stage
Gene therapy — Higher risk/reward profile
Small molecule neuroprotectants — Broader

Investment Recommendations

High-Priority Opportunities

HDAC6-Selective Inhibitors

Rationale: Strong preclinical data for α-synuclein clearance
Risk: Medium
Timeline: 3-5 years to Phase II

Brain-Penetrant Class I Inhibitors

Rationale: Neuroinflammation target
Risk: Medium-High
Timeline: 5-7 years

Sirtuin Modulators

Rationale: Mitochondrial dysfunction target
Risk: Medium
Timeline: 3-5 years

Priority Research Areas

Develop more selective HDAC6 inhibitors with brain penetration

Identify for HDAC activity in CNS

Explore combination therapy approaches

Focus on rare neurodegenerative with clearer readouts

Support academic translation of promising preclinical compounds

External Links

[NeuroWiki Home](/home) Investment Landscape Index

References

Alzheimer's Association. Alzheimer's Disease Facts and Figures (2024)

Parkinson's Foundation. Parkinson's Disease Statistics. 2024 (2024)

Huntington's Disease Society of America. HDSA Statistics. 2024 (2024)

ALS Association. ALS Facts. 2024 (2024)

Simões et al, HDAC6 inhibition reduces α-synuclein aggregation in Parkinson's disease models (2022)

Liu et al, Class I HDAC inhibitors as therapeutic agents for Alzheimer's disease (2020)

Singh et al, Sirtuin activation as a therapeutic approach in neurodegenerative (2023)

Pathway Diagram

The following diagram shows the key molecular relationships involving HDAC Inhibitors for Neurodegeneration — Investment Landscape discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

HDAC Inhibitors for Neurodegeneration — Investment Landscape

HDAC Inhibitors for Neurodegeneration — Investment Landscape

Executive Summary

HDAC Inhibitors for Neurodegeneration — Investment Landscape

Executive Summary

Market Opportunity

Disease Burden

Therapeutic Rationale

Pipeline Overview

Clinical Trials

Preclinical Pipeline

Key Players

Pharmaceutical Companies

Academic Institutions

Biotech Companies

Funding Landscape

NIH Funding (2020-2025)

Investment Trends

Research Gaps

Unmet Needs

Underrepresented Areas

Competitive Landscape

Alternative Epigenetic Approaches

Comparison with Other Mechanisms

Investment Recommendations

High-Priority Opportunities

Priority Research Areas

See Also

External Links

References

Pathway Diagram